ZVRA vs ACAD vs PTCT vs NKTR

For growth investors, Zevra Therapeutics, Inc.

(ZVRA) is the stronger pick with 350. 9% revenue growth year-over-year, versus -43. 9% for Nektar Therapeutics (NKTR). Zevra Therapeutics, Inc. (ZVRA) offers the better valuation at 8. 1x trailing P/E (22. 6x forward), making it the more compelling value choice. Analysts rate Zevra Therapeutics, Inc. (ZVRA) a "Buy" — based on 8 analyst ratings — the highest consensus in this comparison. The "better buy" depends entirely on your goals: growth investors should weight revenue trajectory, value investors should weight P/E and PEG, and income investors should weight dividend yield and streak.

On trailing P/E, Zevra Therapeutics, Inc.

(ZVRA) is the cheapest at 8. 1x versus ACADIA Pharmaceuticals Inc. at 9. 9x. On forward P/E, Zevra Therapeutics, Inc. is actually cheaper at 22. 6x.

Over the past 5 years, PTC Therapeutics, Inc.

(PTCT) delivered a total return of +60. 3%, compared to -72. 3% for Nektar Therapeutics (NKTR). Over 10 years, the gap is even starker: PTCT returned +733. 2% versus ZVRA's -90. 9%. Past returns do not guarantee future results, and the stock with the higher historical return may already have its best growth priced in.

By beta (market sensitivity over 5 years), Zevra Therapeutics, Inc.

(ZVRA) is the lower-risk stock at 0. 63β versus Nektar Therapeutics's 1. 85β — meaning NKTR is approximately 191% more volatile than ZVRA relative to the S&P 500. On balance sheet safety, ACADIA Pharmaceuticals Inc. (ACAD) carries a lower debt/equity ratio of 4% versus 166% for Nektar Therapeutics — giving it more financial flexibility in a downturn.

By revenue growth (latest reported year), Zevra Therapeutics, Inc.

(ZVRA) is pulling ahead at 350. 9% versus -43. 9% for Nektar Therapeutics (NKTR). On earnings-per-share growth, the picture is similar: PTC Therapeutics, Inc. grew EPS 264. 5% year-over-year, compared to -12. 1% for Nektar Therapeutics. Over a 3-year CAGR, ZVRA leads at 118. 8% annualised revenue growth. Higher growth typically commands a higher valuation multiple — check whether the premium P/E or P/S is justified by the growth rate using the PEG ratio.

Zevra Therapeutics, Inc.

(ZVRA) is the more profitable company, earning 78. 2% net margin versus -297. 1% for Nektar Therapeutics — meaning it keeps 78. 2% of every revenue dollar as bottom-line profit. Operating margin tells a similar story: PTCT leads at 49. 5% versus -236. 8% for NKTR. At the gross margin level — before operating expenses — NKTR leads at 100. 0%, reflecting greater pricing power or product mix advantage. Stronger margins indicate durable pricing power, lower cost of revenue, or higher mix of software/services. They are one of the clearest signs of business quality.

On forward earnings alone, Zevra Therapeutics, Inc.

(ZVRA) trades at 22. 6x forward P/E versus 50. 9x for ACADIA Pharmaceuticals Inc. — 28. 3x cheaper on a one-year earnings basis. Analyst consensus price targets imply the most upside for ZVRA: 120. 5% to $24. 25.

None of the stocks in this comparison currently pay a material dividend.

All are effectively zero-yield and should be held for capital appreciation rather than income.

For long-horizon retirement investors, PTC Therapeutics, Inc.

(PTCT) is the stronger choice — it scores higher on the combination of lower volatility, dividend reliability, and long-term compounding (low volatility (β 1. 13), +733. 2% 10Y return). Nektar Therapeutics (NKTR) carries a higher beta of 1. 85 — meaning larger drawdowns in market downturns, which matters significantly when you cannot wait years for a recovery. Both have compounded well over 10 years (PTCT: +733. 2%, NKTR: -59. 1%), confirming both are viable long-term holds — but the lower-volatility option typically results in less emotional selling during corrections. Retirement portfolios generally favour predictability over maximum returns. Consult a financial advisor before making allocation decisions.

Both stocks operate in the Healthcare sector, making this a peer-level intra-sector comparison — the same macro tailwinds and headwinds will affect both.

In terms of investment character: ZVRA is a small-cap high-growth stock; ACAD is a small-cap deep-value stock; PTCT is a small-cap high-growth stock; NKTR is a small-cap quality compounder stock. These fundamental differences mean investors should not choose between them on a single metric — the "better stock" depends entirely on which of these characteristics aligns with your investment strategy.